FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections

GAITHERSBURG, Md.–(BUSINESS WIRE[1])–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat multi-drug resistant bacterial infectious diseases, today announced clearance by the U.S. Food and Drug Administration (FDA) of the company’s Expanded Access IND for PhageBank™ treatment for pneumonia or bacteremia/septicemia due to Acinetobacter baumannii, Pseudomonas aeruginosa or Staphylococcus aureus in COVID-19 patients. “The FDA’s decision...

READ MORE FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections

FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

KENILWORTH, N.J.–(BUSINESS WIRE[1])–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by...

READ MORE FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

Monoclonal Antibody-Based Therapies for Bacterial Infections

Abstract Purpose of review This review highlights recent developments in the development of monoclonal antibodies to treat bacterial disease, including preclinical advances and the status of current clinical trials. Recent Findings Monoclonal antibody (mAb) therapy is becoming increasingly promising in the infectious disease field. Though bacterial exotoxins continue to be a mainstay of mAb targets, searches for protein targets on...

READ MORE Monoclonal Antibody-Based Therapies for Bacterial Infections

Media Release: Meningococcal Disease Outbreak, 21 March 2018

The Ministry of Health and Medical Services has declared an outbreak of meningococcal disease in Fiji. Meningococcal disease is a life-threating disease caused by the bacteria Neisseria meningitidis. It can cause infections in the lining of the brain (meningitis) and in the blood (meningococcemia), or both. These conditions are very serious and can be deadly, but can be treated if...

READ MORE Media Release: Meningococcal Disease Outbreak, 21 March 2018